Peter Attia· MD
and then you know of course we were sequencing cancer gen um you know a ton at the time and we figured out as pd1 and C4 were being clinically developed we began like looking then in retrospect and seeing you know it's these tumors that have a ton of these mutations um they're the ones that are responding like much more likely than other cancer patientscancer types um and so guess what it's the ultraviolet radiation Associated cancers that have like just enormous amounts of mutations like in total and the presence of actually significant numbers usually often times dozens of these mutated neoantigens that's the jargon term that we're we're like coming towards here um and so that explains why the response rates are so high in those cancers smoking related cancers then account for just about all the rest of where pd1 has been efficacious